tbuckley/cabot-search huggingface dataset:
Elderly patients with metastatic castrate-resistant prostate cancer (mCRPC): Safety and efficacy of docetaxel retreatment.
Authors: A. Gernone, A. Pagliarulo, G. Calderoni, V. Pagliarulo
Journal: Journal of Clinical Oncology (2011)

161 Background: Comorbidities are considered a therapeutically limiting problem in elderly patients (pts) with mCRPC. We analysed correlations between comorbidity, toxicity and efficacy of docetaxel re-treatment in pts ≥ 70 years with mCRPC. Methods: Pts were evaluated according to comprehensive geriatric assessment (CGA). From 2003 to 2010, 70 pts ≥ 70 years with mCRPC received 3-wk first line docetaxel therapy followed by retreatment on biochemical disease progression. Each patient was assessed according the Cumulative Illness Score Rating-Geriatrics (CISR-G) manual. The score was 0-4. The median age was 77 (70-84), ECOG PS 0-2, median baseline PSA 180 ng/ml (15-1200). The more frequent comorbidities were hypertension, diabetes, arrhythmias, chronic obstructive pulmonary disease. The endpoints were: PSA response proportion to first-second-third line chemotherapy, median survival in responding patients and toxicity. Results: All pts received a standard 3-wk regimen, dose was reduced by 25% for pts score 4. The incidence of adverse events was relatively low and no pts died on therapy. There were no episodes of neutropenic fever. Pts with score 1-2 were 70% (49 pts); pts with score 3 were 20% (14); pts with score 4 were 10% (7). 70 pts (score 0-4) received first line docetaxel chemotherapy with a median no of cycles 14 (6-18), a median survival of 18 months (mos), PSA response 70%. Of these pts 26 (score 0-3) were re-treated with the same regimen with no of cycles 12 (8-18), a median survival of 14 mos, PSA response 45%, duration of first chemotherapy holiday 5 mos (median). Of these pts, 4 (score 0-3) received third line treatment with no of cycles 10 (6-14), a median survival of 10 mos, PSA response 22%, duration of second chemotherapy holiday 4 mos (median). Of these pts only 1 (score 1) received third re-treatment with 8 cycles, PSA response 20%, third chemotherapy holiday 4 mos. 80% of symptomatic pts reported an improvement in symptoms control with docetaxel chemotherapy. Conclusions: Re-treatment with docetaxel is safe in mCRPC elderly pts despite the association of important comorbidities. Median survival in responding pts was approximately 40 mos from the first to the third line. No significant financial relationships to disclose.
ALK2 Inhibition Via TP-0184 Abrogates Inflammation-Induced Hepcidin Expression and Is a Potential Therapeutic for Anemia of Chronic Disease
Authors: Peter Peterson, Katherine K. Soh, Ye Sol Lee, Wontak Kim, Clifford J. Whatcott, Adam Siddiqui-Jain, David J. Bearss, Steven L. Warner
Journal: Blood (2015)
Survival trends among patients with metastatic bladder cancer in the United States.
Authors: Binay Kumar Shah, Rakesh Mandal
Journal: Journal of Clinical Oncology (2012)

306 Background: The chemotherapy regimens for metastatic bladder cancer (MBC) have evolved over the last two decades. Due to favorable toxicity profile, a combination of cisplatin and gemcitabine is widely used for the treatment of MBC since 2000. It is unclear if the survival trend in MBC has changed over last two decades. This study was conducted to evaluate the relative survival rates for patients with MBC in the United States during 1991-1999 and 2000-2008. Methods: We used the Surveillance, Epidemiology, and End Results (SEER*Stat) program to analyze 6-month and 12-month relative survival rates of AJCC stage-IV bladder cancer patients included in the SEER database. We used Z-test in the SEER*Stat program to compare relative survival rates among cohorts of patients categorized by race, gender, and age groups (&lt;60 and ≥60 years). Results: The dataset comprised 9,819 and 986 patients with AJCC stage-IV bladder cancer among Caucasians and African Americans (AA), respectively. Among Caucasian men (&lt;60 years), 6-month survival rates were 85.4±1.7% (n=442) and 77.9±1.3% (n=1,117) for 1991-1999 and 2000-2008, respectively. Similarly, 12-month survival rates in this group were 68.6±2.2% (n=442) and 60.4±1.5% (n=1,117) for 1991-1999 and 2000-2008, respectively. Thus, both 6-month and 12-month survival rates in 2000-2008 were lower among young Caucasians; and the differences were statistically significant when compared to 1991-1999 (6-month: Z-value = -3.205, p=0.001; 12-month: Z-value= -2.984, p=0.003). The survival rates among AA were not statistically significant. Conclusions: In young Caucasian patients (&lt;60 years) with MBC, 6- month and 12-month relative survival rates were lower for the period 2000-2008 compared to 1991-1999. Further studies may be required to evaluate factors responsible for decreased survival rates among this population.
Acute Graft-Versus-Host Disease Following Umbilical Cord Blood Transplantation: Retrospective Survey Involving 2015 Japanese Patients.
Authors: Shigesaburo Miyakoshi, Takuhiro Yamaguchi, Masahiro Kami, Tomoko Matsumura, Koichiro Yuji, Hiroto Narimatsu, Eiji Kusumi, Hisashi Sakamaki, Yasushi Kouzai, Masaya Okada, Yuko Osugi, Ryuji Kobayashi, Masami Inoue, Satoshi Takahashi, Makoto Murata, Shunro Kai, Koji Kato, Tokiko Nagamura, Shuichi Taniguchi, Shunichi K. Kato
Journal: Blood (2007)
Survival after locoregional recurrence in patients after breast cancer surgery.
Authors: T. Osako, R. Nishimura, Y. Okumura, R. Tashima, Y. Toyozumi, N. Arima
Journal: Journal of Clinical Oncology (2011)

141 Background: The purpose of this study was to investigate factors for survival after locoregional recurrence in patients who underwent mastectomy or breast-conserving therapy (BCT) for primary breast cancer in our hospital. Methods: Out of 3,332 patients operated on from 1989 to 2008, 50 patients had chest wall recurrences after mastectomy (CWR), 40 patients had regional nodal recurrences (RNR), and 24 patients had ipsilateral breast tumor recurrences (IBTR) from 1997 to 2008. To investigate the prognostic factors for survival after locoregional recurrence, we conducted uni- and multivariate analyses of these cases. Results: The median follow-up time was 49.2 months. The 5-year survivals after recurrence of the patients with CWR, RNR and IBRT were 52%, 28%, and 68%, respectively. And the 10-year survivals were 15%, 0%, and 62%, respectively. Furthermore, the 5-year distant metastasis-free survivals were 24%, 13%, and 59%, respectively. In a multivariate analysis of the patients with CWR, type of recurrent nodules (diffuse/single, RR 21.0, p= 0.001), pT (T3 or 4 /T1, RR 11.4, p=0.01), pN (N3/N0, RR 15.5, p= 0.03), Ki67 of primary tumor (&gt;50%/&lt;20%, RR6.7, p=0.02) and ER of the primary tumor (+ / -, RR 2.6, p = 0.02) were independent prognostic factors. In a multivariate analysis of RNR, the method of first line salvage therapy (local /local + systemic, RR 16.1, p = 0.01) was only an independent prognostic factor. In the cases of IBTR, there were no independent prognostic factors for survival after recurrence. Conclusions: Although CWR developed distant metastases within 5 years, the survival depended upon the several biological factors. RNR developed distant metastases within a few years and provided poor prognosis. These suggested that RNR would be the first appearance of systemic metastasis not local disease. In contrast, IBTR provided better prognosis and a salvage treatment cured about 60% of the patients.
Use of Rituximab in a Study Comparing the Thrombopoietin Mimetic Romiplostim with Standard of Care (SOC) in Patients with Immune Thrombocytopenia (ITP),
Authors: Jeffrey Wasser, Ralph Vincent V. Boccia, Roger M. Lyons, Romeo Mandanas, Ingrid Pabinger, Marc Michel IV, Jean-François Viallard, Xuena Wang, Richard Lizambri
Journal: Blood (2011)
Allele Level HLA Matching On Outcomes After Double Umbilical Cord Blood (dUCB) Transplantation for Hematological Malignancies: Stronger Graft Vs. Leukemia with HLA Mismatch
Authors: Claudio G Brunstein, Todd E. Defor, Harriet Noreen, David Maurer, Margaret L. MacMillan, Michael R. Verneris, Phillip McGlave, Daniel Weisdorf, John E. Wagner
Journal: Blood (2012)
Development of leptomeningeal carcinomatosis (LC) in advanced prostate cancer patients: Characteristics of six cases in a single institution.
Authors: C. Sperlich, A. Fontaine, J. Ayllon, I. Van Campenhout
Journal: Journal of Clinical Oncology (2011)

218 Background: In the past months, we have noticed an increasing number of leptomeningeal carcinomatosis (LC) in patients known for advanced prostate cancer (PC). This complication has only been reported in a few patients. Methods: We identified and reviewed the charts of all patients known for advanced PC who later developed LC. We report their characteristics as well as survival. Results: Between March 2009 and April 2010, we identified 6 patients known for advanced PC that showed evidence of LC (median time from diagnosis of prostate cancer to development of LC, 55.8 months). Disease was already metastatic to other sites in all of them, and all had previously showed evidence of castrate refractory prostate cancer (CRPC). All patients maintained LHRH agonist therapy and were treated with prednisone once they showed evidence of CRPC. Most had also been treated with docetaxel (n=5), zoledronic acid (n=4; the remaining 2 patients received either zoledronic acid or denosumab as part of a protocol) and/or other (dasatinib/placebo as part of a protocol, n=1; sunitinib as part of a protocol, n=1). LC was diagnosed a median of 21.2 months after evidence of CRPC, based on clinical findings (cranial nerve[s] involvement [n=6] and nausea and/or ataxia [n=2]) and magnetic resonance imaging (MRI). 2 patients underwent lumbar puncture (negative results). Treatment administered for LC included dexamethasone (n=1), radiation therapy (n=1), or both (n=2). Two patients with poor performance status did not receive any treatment. All patients assessable for response (n=3) showed a partial improvement in their symptoms, but not complete resolution. Median overall survival from development of CRPC and from diagnosis of LC is 23.9 months and 2.7 months, respectively. Conclusions: LC is a newly described site of metastasis in patients with advanced CRPC. It is associated with a late onset and a very poor prognosis. [Table: see text]
Panitumumab in combination with FEC 100 (5-fluorouracil, epidoxorubicin, cyclophosphamide) followed by docetaxel (T) in patients with operable, triple-negative breast cancer (TNBC): Preliminary results of a multicenter neoadjuvant pilot phase II study.
Authors: J. Nabholtz, B. Weber, M. Mouret-Reynier, J. Gligorov, B. P. Coudert, L. Vanlemmens, T. Petit, O. Tredan, I. Van Praagh-Doreau, P. Dubray-Longeras, J. Ferriere, B. Nayl, N. Tubiana-Mathieu, C. Jouannaud, H. Devaud, C. Abrial, E. Planchat, N. Chalabi, F. M. Penault-Llorca, P. J. M. Chollet
Journal: Journal of Clinical Oncology (2011)

e11574 Background: Panitumumab is an antiboby targeting the epidermal growth factor receptor (EGFR) to which a role has been suggested in TNBC. Consequently, we evaluated the combination of a standard chemotherapy (FEC100 followed by T) with panitumumab as neoadjuvant therapy of operable TNBC. Methods: 58 patients with stage II-IIIA disease were prospectively included in this multicentre pilot study. Systemic therapy (ST) consisted of 4 cycles of FEC100 (500/100/500 mg/m2) q.3 weeks followed by 4 cycles of T (100 mg/m2) q.3 weeks, in combination with panitumumab (9mg/kg) for 8 cycles q.3 weeks. All patients underwent surgery at completion of ST. Complete pathologic response (pCR) was the primary endpoint (Sataloff : J Am Coll Surg 1995 ; Chevallier : Am J Clin Oncol 1993), with toxicity and biologic ancillary studies as secondary endpoints. Results: Patients characterisctics are as follows : mean age 50 [38-64] ; T2 : 81%, T3 : 19% (mean tumor size : 42 mm [25-80]) ; N0 : 73% and N1 : 27%; invasive ductal carcinoma : 87%; Scarff-Bloom-Richardson Grade III : 56%, grade II : 44%. The median number of cycles was : FEC 100 : 4 [4-4], T : 4 [2-4], Panitumumab : 8 [4-8]. Preliminary results on 17 patients showed a pCR of 65% (Sataloff) and 53% (Chevallier) with an overall clinical response rate of 80% (47% CR). Conservative surgery was performed in 87% of cases. Skin toxicity was the main side-effect : grade II : 69%, grade III : 19%. Neutropenia grade IV : 27%, febrile neutropenia : 7%, infection : 0%. Hand-foot syndrome grade III : 12%. Ungueal toxicity grade III : 6%, grade II : 12%. Conclusions: These preliminary results suggest that panitumumab in combination with FEC100 followed by T appears efficacious with acceptable toxicity in the neoadjuvant therapy of operable TNBC. Updated results on 40 patients will be presented at the meeting.
Virtual HDR SBRT for localized prostate carcinoma: Efficacy and quality-of-life assessment.
Authors: Donald B. Fuller, Reza Shirazi, John Naitoh, George Mardirossian
Journal: Journal of Clinical Oncology (2012)

45 Background: We designed a CyberKnife (CK) prostate Stereotactic Body Radiotherapy (SBRT) method to recapitulate HDR fractionation and target volume coverage (“Virtual HDR”). We report 4 year efficacy, toxicity and quality of life (QoL) outcomes. Methods: Eligible patients had low- (Gleason &lt; 6, PSA &lt; 10 ng/mL, &lt; T2bN0) or intermediate-risk (Gleason &lt; 6 with PSA 10.01 – 20 ng/mL or Gleason 7 with PSA &lt; 10 ng/mL, &lt; T2bN0) prostate cancer. A dose of 38 Gy/4 fractions was given to &gt; 95% of the PTV; with “HDR-like” bladder, urethral and rectal dose constraints, and “HDR-like” dose escalation in the PTV. Toxicities were assessed using CTCAE3.0 criteria. QoL was assessed using the Expanded Prostate Cancer Index Composite (EPIC). Results: Since July 2006, 59 patients were treated. Two were lost to follow-up and 6 have been followed &lt; 6 months, leaving 51 (32 low- and 19 intermediate-risk) patients for analysis. Median f/u is 42 months (range, 6-60). 4-year actuarial biochemical-disease free survival is 98% (ASTRO, Phoenix). Freedom from local and distant relapse is 100% and 98%. Median baseline PSA of 6.3 ng/mL (range 1.0 – 14.1) decreased to 0.1 ng/mL by 48 months. Acute grade 2 GU and GI toxicity rates were 22% and 4%, respectively (0% Grade 3+). Three (6%) late Grade 3 GU toxicities occurred at 18, 48 and 48 months. No grade 3+ GI toxicity occurred. Late grade 2 GU and GI toxicity rates were 18% and 2%, respectively. Only 2 patients (4%) had ongoing late &gt; grade 2 GU toxicity at last follow-up (0% GI). Mean EPIC urinary and bowel scores decreased at 2 months, with subsequent improvement and stability to 48 months. Mean EPIC sexual scores gradually declined to 48 months. Of patients potent at baseline, 63% were potent at 3 years, including 100% &lt; age 60, 64% age 61-70 and 60% &gt; age 70. Conclusions: To 4 years, HDR-like CK SBRT for low- and intermediate-risk prostate cancer results in a very low PSA nadir and relapse rate, minimal toxicity and a favorable QoL outcome, with an age-dependent potency preservation rate. The occasional occurrence of late grade 3 urethral stricture can likely be reduced by better patient selection (caution re: patients with significant pre-existing uropathy). Acute and late grade 2 GU toxicity usually resolves with conservative management.
The Pim Kinase Inhibitor SGI-1776 Chemosensitizes Multidrug Resistant Cells by Both Inhibiting Drug Transport by ABCB1 and ABCG2 and Decreasing ABCB1 and ABCG2 Surface Expression On Cells That Overexpress Pim-1.
Authors: Karthika Natarajan, Jasjeet Bhullar, Suneet Shukla, Mehmet Burcu, Suresh V. Ambudkar, Maria R. Baer
Journal: Blood (2012)
Systemic inflammatory response to predict clinical outcome in patients with resected pancreatic cancer treated with adjuvant gemcitabine monotherapy.
Authors: Soichiro Morinaga, Takuo Watanabe, Masakatsu Numata, Yo Mikayama, Hiroshi Tamagawa, Naoto Yamamoto, Manabu Shiozawa, Makoto Akaike
Journal: Journal of Clinical Oncology (2012)

223 Background: Systemic inflammatory response (SIR) has been shown to associate with poor outcome in either inoperable or operable pancreatic cancer. However, whether the presence of a SIR predicts poor clinical outcome of pancreatic cancer patients in adjuvant setting is unclear. The aim of present study was to determine the relationship between SIR, as evaluated by Modified Glasgow prognostic score (mGPS), and outcome of pancreatic cancer patients treated with adjuvant chemotherapy. Methods: A total of 42 resected pancreatic cancer patients were analyzed for mGPS before adjuvant gemcitabine chemotherapy. The mGPS was constructed as follows: patients with both an elevated C-reactive protein (&gt; 0.3mg/dl) and hypoalbuminaemia (&lt; 3.5mg/dl) were allocated a score of 2. Patients with one or none of these abnormalities were allocated a score of 1or 0, respectively. Results: There were 25 patients assigned to score 0, 12 patients to score 1, and 5 patients to score 2. The median OS in patients with score 0, score 1, and score 2 were 23.9 months, 10.3 months, and 9.9 months, respectively. The DFS in patients with score 0, score 1, and score 2 were 11.0 months, 5.9 months, and 3.6 months, respectively. The OS and DFS after surgery of the patients with SIR (score 1 and 2) were significantly poorer than that of the patients with score 0 (P=0.0278 for OS, P=0.0011 for DFS by log-rank test). Conclusions: The presence of SIR, as evaluated by Modified Glasgow prognostic score (mGPS), predicts poor clinical outcome in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy.
Relationship of recent pregnancy and cytologic atypia in the contralateral breast of patients with breast cancer.
Authors: E. Revesz, C. M. Zalles, D. Ivancic, K. P. Bethke, N. M. Hansen, J. S. Jeruss, S. A. Khan
Journal: Journal of Clinical Oncology (2011)

149 Background: Although early parity protects against breast cancer later in life, it is a risk factor in the years following pregnancy, particularly when child-bearing is delayed. In a separate study, we have reported that these pregnancy-associated breast cancers (PABC) are more likely to be hormone receptor (HR) negative; we have previously found that random fine needle aspiration (rFNA) of the contralateral breast (CB) frequently have atypia in women with HR negative breast cancer. We now report an analysis of the cytological features of contralateral rFNA in relation to recent parity, with the goal of assessing cytological features which may be risk factors for PABC. Methods: Women with breast cancer undergoing surgery between 2006 and 2008 were enrolled in a prospective study of rFNA of the CB. Cytological analysis was performed on all the samples, using two scoring systems, Masood and Zalles (M and Z). Linear regression analyses were performed relating each score to interval from last pregnancy, stratified for parity, and adjusted for age. Results: Eighty-two patients had rFNA and cytologic analysis. The parous group’s (n=52) interval since last pregnancy was inversely correlated with the overall M score (p=0.034); pleomorphism and (p=0.047 and p=0.013 respectively). M score was also related to age at last pregnancy (p=0.026) as were pleomorphism and chromatin pattern (p=0.044 and 0.035 respectively). In the nulliparous group (n=30), there were no significant relationships between any of the cytological parameters or age. Conclusions: The CB of women with recent parity display specific cytological abnormalities that are related to risk of breast cancer, particularly HR negative breast cancer. This observation affords the opportunity to further evaluate rFNA as a tool for breast cancer risk assessment following pregnancy, and to identify molecular correlates of nuclear cytological abnormalities that may serve as targets for prevention of ER negative breast cancer.
Long-term self-renewing human epicardial cells generated from pluripotent stem cells under defined xeno-free conditions
Authors: Xiaoping Bao, Xiaojun Lian, Timothy A. Hacker, Eric G. Schmuck, Tongcheng Qian, Vijesh J. Bhute, Tianxiao Han, Mengxuan Shi, Lauren Drowley, Alleyn T. Plowright, Qing-Dong Wang, Marie-Jose Goumans, Sean P. Palecek
Journal: Nature Biomedical Engineering (2016)
Risk factors for outcome in Hispanic patients with breast cancer with central nervous system (CNS) metastases.
Authors: L. J. Schwarz, T. Vidaurre, S. P. Neciosup, J. A. Pinto, G. Ferreyros, H. Gomez
Journal: Journal of Clinical Oncology (2011)

e11523 Background: Current prognostic scores for patients with CNS metastases includes RPA, BSBM, SIR, GPA and Rades score, there were developed from several types of primary tumors. Due to breast cancer have unique biological and treatment characteristics; our aim was to identify risk factors for post-SNC recurrence survival in Hispanic breast cancer patients. Methods: We indentify retrospectively 157 breast cancer patients with CNS metastases that underwent radiation treatment and subsequent medical management at the Instituto Nacional de Enfermedades Neoplasicas (Lima, Perú) between 2003 and 2009. Phenotypes were determined by immunohistochemistry and categorized in [ER + and / or PR +, HER2-], [ER + and / or PR +, HER2 +], triple-negative [ER-, PR-, HER2-] and Her-2 [ER-, PR-, HER2 +]. Post-SNC recurrence survival was calculated from date of CNS metastases to death or last follow-up. We used the Kaplan Meier method to calculate survival in months (mo) and log-rank test to determine statistical significance between groups: Results: The median of post-SNC survival was 4.9 mo. There was not significant differences between phenotypes (P=0.053); however, differences between triple negative (3.6 Mo) VS non-triple negative (5.2 mo) groups were significant (P=0.013). Also, we observed differences when was compared ECOG <2 (6.2 months) VS ECOG ≥ 2 (3.5 months; P=0.037); extra-cranial controlled disease (6.5 mo) VS extra-cranial not controlled disease (3.6 mo; P < 0001); time to onset SNC metastases, ≤8 mo (2 mo) VS >8 mo (5.2 mo; P=0.016). In this group were 22 patients with leptomeningeal carcinomatoses (LMC) (median survival: 3.1 mo), from which 77.2% were triple negative; 72.7% were < 50 years and 68% were pre-menopausal women. Conclusions: The most important risk factors in breast cancer patients with CNS metastases are triple negative phenotype, ECOG status, time to onset of SNC metastases and extra-cranial disease control. A group with shorter post-SNC recurrence survival constitutes patients with LMC that are mostly pre-menopausal, younger than 50 years and with triple negative phenotype. This data need to be validated prospectively.
Recurrent Mutations Found In Acute Monocytic Leukemia by Exomes Sequencing
Authors: Xiao-Jing Yan, Jie Xu, Zhao-Hui Gu, Chun-Ming Pan, Gang Lv, Keqin Kathy Li, Jian-Qing Mi, Shen Yang, Huai-Dong Song, Sai-Juan Chen, Zhu Chen
Journal: Blood (2010)
A New Protocol for Efficient and Non-Toxic Transfection of siRNA Into Leukemic Cell Lines and Primary Cells – a Direct Comparison Between Nucleofection and Accell Delivery Using Stem Cell Related Antigens As Validation Tools
Authors: Hanne Østergaard Larsen, Anne Stidsholt Roug, Claus Svane Sondergaard, Peter Hokland
Journal: Blood (2011)